Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
Posted on: Thursday, 23 August 2007, 09:14 CDT
SOUTH SAN FRANCISCO, Calif., Aug. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. announced today that William D. Young, CEO and Chairman, is scheduled to present a corporate overview at the Thomas Weisel Partners Healthcare Conference 2007 on Wednesday, September 5, 2007 at 3:15 p.m. (Eastern Time) at the Four Seasons Hotel in Boston, Massachusetts.
To access the live audio broadcast or the subsequent archived recording, log on to http://www.monogrambio.com/ and go to the investor relations section ("Investors/Media" tab) and click on the "Events & Webcasts" link provided on the sidebar menu on the page.
About Monogram Biosciences, Inc.
Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com/.
Contacts: Alfred G. Merriweather Chief Financial Officer Tel: 650 624-4576 amerriweather@monogrambio.com Jeremiah Hall Feinstein Kean Healthcare Tel: 415 677-2700 jeremiah.hall@fkhealth.com
Monogram Biosciences, Inc.
CONTACT: Alfred G. Merriweather, Chief Financial Officer of MonogramBiosciences, Inc., +1-650-624-4576, amerriweather@monogrambio.com; or JeremiahHall of Feinstein Kean Healthcare, +1-415-677-2700,jeremiah.hall@fkhealth.com
Source: PRNewswire-FirstCall
Related Articles
- YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
- Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
- Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
- Monogram Appoints Oncologist to Board of Directors
- Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
- View Individual Analysis of the Top 58 Healthcare Advertising Companies Inside the UK Today
- Monogram Provides Update on Trofile(TM) Assay
- Lotus Director Honored Among 2007 Health Care Heroes
- Healthcare: MD Smith Joins Exodus From GCI Healthcare UK
- Monogram Announces Year End 2005 Financial Results
 |
 |
User Comments (0)
RSS Feeds